Taiwan Liposome Company Completes US IPO

San Diego – January 3, 2019 – Cooley advised Taiwan Liposome Company on its $22.7 million initial public offering of 3,915,550 American Depository Shares – each representing two common shares. Partners Charlie Kim, Robert Phillips, James Lu and David Peinsipp led the Cooley team advising Taiwan Liposome Company.

Cantor acted as book-running manager for the offering. CLSA, HC Wainwright & Co., Janney Montgomery Scott and Laidlaw & Company UK Ltd. acted as book-runners.

Taiwan Liposome Company, whose securities now trade on the Nasdaq Global Market under the symbol “TLC,” is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology. 

Cooley has now represented the only two Taipei Exchange-listed companies to go public in the US to date – TLC and ASLAN Pharmaceuticals in June 2018

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,000+ lawyers across 13 offices in the United States, China and Europe.

 
Related Contacts
Charlie Kim Partner, San Diego
Robert Phillips Partner, San Francisco
James Lu Partner, Shanghai
David Peinsipp Partner, San Francisco
Kristin VanderPas Partner, San Francisco
Sara Semnani Associate, Los Angeles
Chen Chen Associate, Palo Alto
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Robert Paster Associate, New York
Susan Cooper Philpot Partner, San Francisco
Mark Windfeld-Hansen Partner, Palo Alto
Barbara Mirza Partner, Los Angeles
Courtney Thorne Associate, Boston
Francis Wheeler Partner, Colorado
Daniel I. Goldberg Partner, New York
Josh Kaufman Partner, New York
Monica Xu Associate, Shanghai
Pan Chen Legal Consultant, Shanghai
Alexander Davis Associate, San Diego